By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Sepracor Inc. et al. v. Sandoz, Inc.
3:08-cv-01584; filed March 31, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Sepracor's Clarinex-D® (desloratidine and pseudoephedrine sulfate, used to treat allergies). View the complaint here. [NB: This case was consolidated with 3:07-cv-04213, reported here, and is one of nine cases consolidated with this lead case.]
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc. et al.
3:08-cv-01583; filed March 31, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,006,528 ("Carbostyril Derivatives," issued April 9, 1991) and 6,977,257 ("Aripiprazole Oral Solution," issued December 20, 2005) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia). View the complaint here.
Endo Pharmaceuticals Inc. et al. v. Actavis South Atlantic LLC
2:08-cv-01563; filed March 28, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 5,958,456 ("Controlled Release Formulation (Albuterol)," issued September 28, 1999) following a paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Endo's Opana® ER (oxymorphone hydrochloride, used to treat moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time). View the complaint here.
Comments